Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.42 |
| ▸ | CMA1 | P23946 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.34 |
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.34 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31287140 | 0.83 | NPC1 (0.40) | AHRCMA1GSK3BCDK5CDK5R1 | |
| SCHEMBL21910247 | 0.78 | GSK3B (0.47) | AHRCMA1GSK3BCDK5CDK5R1 | |
| SCHEMBL24192469 | 0.77 | AHR (0.38) | AHRCMA1CDK5CDK5R1PDK2 | |
| SCHEMBL21874251 | 0.77 | AHR (0.38) | AHRCMA1PDK2PDE3BPDE3A | |
| SCHEMBL658555 | 0.77 | AHR (0.46) | AHRCMA1PDK2PDE3BPDE3A | |
| SCHEMBL15806897 | 0.77 | CYP2C19 (0.42) | AHRCMA1PDK2PDE3BPDE3A | |
| SCHEMBL29930637 | 0.77 | AHR (0.46) | AHRCMA1PDK2PDE3BPDE3A | |
| SCHEMBL6073595 | 0.77 | PDE3B (0.44) | AHRPDK2PDE3BPDE3AEIF2AK2 | |
| SCHEMBL21964248 | 0.77 | AHR (0.35) | AHRCMA1PDK2PDE3BPDE3A | |
| SCHEMBL29073521 | 0.76 | CA12 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| WO-2024064316-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 INHIBITORS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116444493-A | Derivative containing double parallel rings, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110461828-B | IP6K inhibitors | 武田药品工业株式会社 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022099066-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3887358-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-10968178-B2 | IP6K inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-2288605-B1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014090692-A1 | NOVEL BI-RING PHENYL-PYRIDINES/PYRAZINES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-8329725-B2 | Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2012-12-11 | — | — | US | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-2411379-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| EP-2288605-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010109005-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009149819-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391674-B2 | Heterocyclic compounds for the treatment of epilepsy | SLC6A11, SCN1A, SCN1B | AHR 1052/4885CMA1 3722/4885GSK3B 1687/4885 |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | AHR 4156/4885CMA1 3278/4885GSK3B 1/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | AHR 1052/4885CMA1 3722/4885GSK3B 1687/4885 |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | AHR 952/4885CMA1 4791/4885GSK3B 3376/4885 |
| US-10968178-B2 | IP6K inhibitors | IP6K1, IP6K2, IP6K3 | AHR 4866/4885CMA1 3896/4885GSK3B 2923/4885 |
| US-20250304558-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, KCNH1 | AHR 1245/4885CMA1 3312/4885GSK3B 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.